Insmed Incorporated (NASDAQ:INSM) Position Increased by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC boosted its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 48.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,087 shares of the biopharmaceutical company's stock after purchasing an additional 9,170 shares during the quarter. Orion Portfolio Solutions LLC's holdings in Insmed were worth $2,050,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Castleark Management LLC grew its holdings in Insmed by 159.9% in the third quarter. Castleark Management LLC now owns 43,300 shares of the biopharmaceutical company's stock valued at $3,161,000 after purchasing an additional 26,640 shares during the period. Wellington Management Group LLP grew its stake in Insmed by 2.6% during the third quarter. Wellington Management Group LLP now owns 962,459 shares of the biopharmaceutical company's stock worth $70,260,000 after buying an additional 24,025 shares during the period. Two Sigma Advisers LP grew its stake in Insmed by 32.9% during the third quarter. Two Sigma Advisers LP now owns 392,700 shares of the biopharmaceutical company's stock worth $28,667,000 after buying an additional 97,300 shares during the period. Soros Fund Management LLC grew its stake in Insmed by 1.7% during the third quarter. Soros Fund Management LLC now owns 478,601 shares of the biopharmaceutical company's stock worth $34,938,000 after buying an additional 7,901 shares during the period. Finally, Polar Asset Management Partners Inc. grew its stake in Insmed by 217.7% during the third quarter. Polar Asset Management Partners Inc. now owns 57,500 shares of the biopharmaceutical company's stock worth $4,198,000 after buying an additional 39,400 shares during the period.

Analyst Ratings Changes

Several equities research analysts have issued reports on INSM shares. JPMorgan Chase & Co. boosted their price objective on shares of Insmed from $74.00 to $83.00 and gave the stock an "overweight" rating in a research note on Friday, November 22nd. HC Wainwright reiterated a "buy" rating and set a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. Bank of America upped their target price on shares of Insmed from $84.00 to $86.00 and gave the company a "buy" rating in a research note on Wednesday, October 9th. Truist Financial reiterated a "buy" rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $83.67.

Insider Transactions at Insmed

In other news, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the transaction, the insider now directly owns 106,134 shares in the company, valued at approximately $7,951,559.28. This trade represents a 11.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 4.60% of the company's stock.

Insmed Trading Down 0.6 %

Shares of NASDAQ:INSM traded down $0.42 during trading on Friday, reaching $71.63. 1,463,062 shares of the company's stock traded hands, compared to its average volume of 2,203,438. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The company has a 50 day moving average of $72.40 and a 200-day moving average of $70.82. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. Insmed's revenue for the quarter was up 18.1% on a year-over-year basis. During the same period in the prior year, the company earned ($1.10) EPS. Equities analysts anticipate that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.